Evaluation of subunit vaccines against feline immunodeficiency virus infection.
Subunit vaccines prepared against feline immunodeficiency virus (FIV) infection were evaluated in two trials. First, cats were immunized with bacterial expression products of an envelope fragment that contained the V3 neutralization domain of the FIV surface protein fused to either galactokinase (K-SU3) or glutathione-S-transferase (G-SU3). Quantitative and qualitative differences in the humoral immune response were observed with three adjuvants of which Quil A was the best in terms of total and virus neutralizing antibody. Notwithstanding the responses induced, 19 of 20 immunized cats did not resist challenge and became infected. To determine whether priming with a live viral vector would confer protection, cats were inoculated oronasally and subcutaneously with a feline herpesvirus (FHV) mutant expressing the FIV env gene; two booster immunizations followed using the K-SU3 product in either Quil A or a mineral oill Al(OH)3 adjuvant. FIV-specific antibody responses were only weak, and the vaccinates did not withstand challenge with a low dose of homologous virus.
Verschoor
E J
EJ
Virology Unit, Institute of Infectious Diseases and Immunology, Veterinary Faculty, University Utrecht, The Netherlands.
Willemse
M J
MJ
Stam
J G
JG
van Vliet
A L
AL
Pouwels
H
H
Chalmers
S K
SK
Horzinek
M C
MC
Sondermeijer
P J
PJ
Hesselink
W
W
de Ronde
A
A
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis / Q000097:blood; D002415:Cats; D004797:Enzyme-Linked Immunosorbent Assay; D005069:Evaluation Studies as Topic; D016181:Feline Acquired Immunodeficiency Syndrome / Q000097:blood / Q000517:prevention & control*; D015686:Gene Products, env / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D016089:Immunodeficiency Virus, Feline / Q000235:genetics / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000627:therapeutic use; D014760:Viral Fusion Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000627:therapeutic use*
D000914:Antibodies, Viral; D015686:Gene Products, env; D014613:Vaccines, Attenuated; D014760:Viral Fusion Proteins; D014765:Viral Vaccines